EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Current aspects of cellular immunotherapy for melanoma

Chulpan B. Kharisova, Anna V. Gorodilova, Yuriy P. Mayasin, Ivan Yu. Filin, Kristina V. Kitaeva, Victor V. Valiullin, Albert A. Rizvanov, Valeriya V. Solovyeva

Kazan medical journal · 28.07.2026 · 107 (4) · 582-597

DOI: 10.17816/kmj690309 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kazan medical journal, online erschienen am 28.07.2026. Verfasst von Chulpan B. Kharisova und 7 weiteren Autor:innen. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma is one of the most aggressive and therapy-resistant cancers, characterized by a high metastatic potential and a steadily increasing incidence. This review analyzes current approaches to cellular immunotherapy for melanoma, including tumor-infiltrating lymphocyte (TIL) therapy, TCR- and CAR-T-cell technologies, the use of NK cells, NKT cells, B cells, dendritic cells, macrophages, and immune checkpoint inhibitors. TIL therapy and PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors have demonstrated the greatest clinical efficacy, improving overall and progressionfree survival in a subset of patients with advanced melanoma. TCR and CARTcell approaches have high potential due to their specific recognition of tumor antigens; however, their use is limited by toxicity, poor infiltration of solid tumors, and the difficulty of target selection. NK and NKTcell therapies have favorable safety profiles but require further optimization to increase antitumor activity and cell persistence in vivo. Bcell and dendriticcellbased vaccine strategies can induce antigenspecific immune responses and are considered promising adjuvant treatments. The development of CARmacrophages is a new direction in cellular therapy for solid tumors. An analysis of clinical trial data shows that combination approaches that combine cellular therapy with immune checkpoint inhibitors or standard treatments are the most effective. Despite progress, the issues of toxicity, durability of the antitumor response, and overcoming the immunosuppressive tumor microenvironment remain unresolved, highlighting the need for further research in personalized immunotherapy for melanoma.

Zitieren

APA

Kharisova, C. B., Gorodilova, A. V., Mayasin, Y. P., Filin, I. Y., Kitaeva, K. V., Valiullin, V. V., Rizvanov, A. A., & Solovyeva, V. V. (2026). Current aspects of cellular immunotherapy for melanoma. Kazan medical journal, 107(4), 582-597. https://doi.org/10.17816/kmj690309

Vancouver

Kharisova CB, Gorodilova AV, Mayasin YP, Filin IY, Kitaeva KV, Valiullin VV, et al. Current aspects of cellular immunotherapy for melanoma. Kazan medical journal. 2026;107(4):582-597. doi:10.17816/kmj690309

BibTeX
@article{Kharisova2026,
  author = {Kharisova, Chulpan B. and Gorodilova, Anna V. and Mayasin, Yuriy P. and Filin, Ivan Yu. and Kitaeva, Kristina V. and Valiullin, Victor V. and Rizvanov, Albert A. and Solovyeva, Valeriya V.},
  title = {Current aspects of cellular immunotherapy for melanoma},
  journal = {Kazan medical journal},
  year = {2026},
  volume = {107},
  number = {4},
  pages = {582--597},
  doi = {10.17816/kmj690309}
}
Kostenlos starten →